RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Orchard Therapeutics Stock

Orchard Therapeutics EBIT 2024

Orchard Therapeutics EBIT

-115.75 M USD

Ticker

ORTX

ISIN

US68570P1012

WKN

A2N8KD

In 2024, Orchard Therapeutics's EBIT was -115.75 M USD, a 10% increase from the -105.23 M USD EBIT recorded in the previous year.

The Orchard Therapeutics EBIT history

YEAREBIT (undefined USD)
2028e-
2027e-
2026e-
2025e-
2024e-
2023e-
2022-
2021-
2020-
2019-
2018-
2017-
2016-

Orchard Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Orchard Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Orchard Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Orchard Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Orchard Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Orchard Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Orchard Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Orchard Therapeutics’s growth potential.

Orchard Therapeutics Revenue, EBIT and net profit per share

DateOrchard Therapeutics RevenueOrchard Therapeutics EBITOrchard Therapeutics Net Income
2028e118.52 M undefined-78.85 M undefined-90.37 M undefined
2027e200.8 M undefined-34.42 M undefined3.87 M undefined
2026e155.24 M undefined-51.3 M undefined-16.78 M undefined
2025e98.86 M undefined-75.87 M undefined-40.02 M undefined
2024e56.64 M undefined-115.75 M undefined-348.58 M undefined
2023e28.1 M undefined-105.23 M undefined-373.11 M undefined
202222.66 M undefined-125.31 M undefined-150.66 M undefined
20211.68 M undefined-140.43 M undefined-144.58 M undefined
20202.6 M undefined-153.23 M undefined-151.98 M undefined
20192.51 M undefined-172.87 M undefined-163.42 M undefined
20182.08 M undefined-235.03 M undefined-230.5 M undefined
20170 undefined-38.51 M undefined-39.74 M undefined
20160 undefined-19.2 M undefined-19.09 M undefined

Orchard Therapeutics stock margins

The Orchard Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Orchard Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Orchard Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Orchard Therapeutics's sales revenue. A higher gross margin percentage indicates that the Orchard Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Orchard Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Orchard Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Orchard Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Orchard Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Orchard Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Orchard Therapeutics Margin History

Orchard Therapeutics Gross marginOrchard Therapeutics Profit marginOrchard Therapeutics EBIT marginOrchard Therapeutics Profit margin
2028e70.08 %-66.53 %-76.25 %
2027e70.08 %-17.14 %1.93 %
2026e70.08 %-33.05 %-10.81 %
2025e70.08 %-76.75 %-40.49 %
2024e70.08 %-204.36 %-615.43 %
2023e70.08 %-374.52 %-1,327.89 %
202270.08 %-553 %-664.87 %
202186.31 %-8,358.93 %-8,605.95 %
202066.92 %-5,893.46 %-5,845.38 %
201968.13 %-6,887.25 %-6,510.76 %
201879.33 %-11,299.52 %-11,081.73 %
201770.08 %0 %0 %
201670.08 %0 %0 %

Orchard Therapeutics Aktienanalyse

What does Orchard Therapeutics do?

Orchard Therapeutics PLC is a biopharmaceutical company based in London. It was founded in 2015 and is traded on the NASDAQ and the London Stock Exchange. The company focuses on the development and commercialization of gene therapy products for rare and life-threatening diseases for which there is currently no cure. Orchard Therapeutics has its roots in the research and development of gene therapy products at the University College London (UCL) and the Great Ormond Street Hospital for Children (GOSH). The company has a strong partnership with these institutions and utilizes their resources for the development of new therapies. This close collaboration allows Orchard Therapeutics to focus on the research and development of gene therapy products for rare diseases. The business model of Orchard Therapeutics is to develop gene therapies for rare diseases that currently have no treatment options. These products are then licensed to pharmaceutical companies that are responsible for the production and marketing of the products. Orchard Therapeutics then receives a licensing fee and potential milestone payments for the sale of the products. Orchard Therapeutics has various divisions specializing in the development of gene therapies for different diseases. For example, the hemophilia division develops gene therapies for people with hemophilia, a genetic disease that impairs blood clotting. Other divisions focus on the development of gene therapies for muscular dystrophy, B-cell immunodeficiency, and chronic granulomatosis. The company has a broad portfolio of products currently in development. One of the most well-known products is "OTL-101," a gene therapy for the treatment of adenosine deaminase deficiency immunodeficiency (ADA-SCID), a severe type of immunodeficiency that can lead to infections and serious illness. Another important gene therapy is "OTL-103," which is used for the treatment of Wiskott-Aldrich syndrome (WAS), a rare genetic disorder that affects the immune system. Orchard Therapeutics manages to develop gene therapies for rare diseases by using a unique technology platform. This platform includes the use of lentiviruses that can insert genetic information into cells of the body. The gene therapies developed on this platform can help replace defective or missing genes with functional genes to treat diseases. Overall, Orchard Therapeutics is an emerging biotechnology company that focuses on the development of gene therapy products for rare and life-threatening diseases. The company has a strong partnership with leading medical institutions and utilizes a unique technology platform to develop gene therapies. With a wide range of products in development and potential groundbreaking therapies in the pipeline, Orchard Therapeutics is expected to play a significant role in the development of gene therapies for rare diseases. Orchard Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Orchard Therapeutics's EBIT

Orchard Therapeutics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Orchard Therapeutics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Orchard Therapeutics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Orchard Therapeutics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Orchard Therapeutics stock

How much did Orchard Therapeutics achieve in EBIT for the current year?

In the current year, Orchard Therapeutics has achieved an EBIT of -115.75 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Orchard Therapeutics.

How has the EBIT of Orchard Therapeutics developed in recent years?

The EBIT of Orchard Therapeutics has increased by 9.995% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Orchard Therapeutics?

The EBIT of Orchard Therapeutics is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Orchard Therapeutics pay?

Over the past 12 months, Orchard Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Orchard Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Orchard Therapeutics?

The current dividend yield of Orchard Therapeutics is .

When does Orchard Therapeutics pay dividends?

Orchard Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Orchard Therapeutics?

Orchard Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Orchard Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Orchard Therapeutics located?

Orchard Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Orchard Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Orchard Therapeutics from 8/31/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/31/2024.

When did Orchard Therapeutics pay the last dividend?

The last dividend was paid out on 8/31/2024.

What was the dividend of Orchard Therapeutics in the year 2023?

In the year 2023, Orchard Therapeutics distributed 0 USD as dividends.

In which currency does Orchard Therapeutics pay out the dividend?

The dividends of Orchard Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Orchard Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Orchard Therapeutics

Our stock analysis for Orchard Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Orchard Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.